Jerini's icatibant receives positive opinion in EU
25th April 2008
By Staff Writer
Jerini has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for icatibant in the treatment of acute attacks of hereditary angioedema.
RELATED ARTICLESJerini collaborates with Baxter for protein purification
11 Jan 2008
Jerini regains rights to Icatibant from Abbott
6 Sep 2007
Jerini and UCL Institute of Ophthalmology collaborate for AMD treatment
11 Dec 2007
Jerini and PRP collaborate to develop formulations for eye diseases
11 Apr 2008
Jerini submits Icatibant to FDA
29 Oct 2007
COMPANIES MENTIONEDMedicines Company, The
WHITE PAPERS
No White Papers Available
The committee will now recommend that the European Commission grant marketing authorization for Icatibant, which is normally issued within 67 days from adoption of the Committee for Medicinal Products for Human Use (CHMP) opinion.
In addition, Jerini has received a not approvable letter from the FDA for its new drug application (NDA) for icatibant in the treatment of hereditary angioedema (HAE). The company is reviewing the contents of the letter and plans to meet with the FDA at the earliest opportunity to address the agency's concerns.
Jens Schneider-Mergener, CEO of Jerini, said: "Icatibant will claimed to be the first product to be approved in all European countries for the acute treatment of HAE, and our sales and marketing teams are in place and ready to launch following the European Commission's marketing authorization."
-----------
In der Vielfalt der Möglichkeiten und Antworten liegt der Schlüssel und die Weisheit der Massen. |
1
|
